Skip to main content
NeoImmuneTech, Inc. logo

NeoImmuneTech, Inc. — Investor Relations & Filings

Ticker · 950220 ISIN · KR8840140006 LEI · 254900489QR747TPTT13 KO Professional, scientific and technical activities
Open in API
Filings indexed 217 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country US United States of America
Listing KO 950220

About NeoImmuneTech, Inc.

https://www.neoimmunetech.com/en

NeoImmuneTech, Inc. is a clinical-stage, T cell-focused biopharmaceutical company dedicated to the development of novel immuno-therapeutics. The company's lead asset is NT-I7 (efineptakin alfa), a long-acting human interleukin-7 (IL-7) fusion protein designed to amplify and reinvigorate T cells. This core technology aims to enhance the immune system's ability to eliminate cancer cells and pathogens. NT-I7 is being developed as a foundational immuno-oncology therapy for use in combination with other cancer treatments, such as checkpoint inhibitors, as well as for applications in infectious diseases. The company's research is focused on leveraging T cell amplification to address a wide range of challenging diseases.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled “분기보고서” covering the period January 1, 2026 to March 31, 2026 (제13기 1분기), filed with the Financial Supervisory Service and Korea Exchange. It contains detailed quarterly financial statements, business overview, R&D activities, contracts and financial tables for the quarter. It is not merely an announcement of a report but the full quarterly interim report itself. Hence it matches the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-15 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 98% confidence The document is a statutory report filed by an officer (reported as an 임원, director) disclosing his shareholdings and recent transactions (acquisitions/disposals) of the company’s securities. This matches the definition of a Director’s Dealing report (insider transaction disclosure), not a broader financial report or announcement. Therefore, the correct classification is DIRS.
2026-05-14 Korean
주권매매거래정지 (주식의 병합, 분할 등 전자등록 변경, 말소)
Share Issue/Capital Change Classification · 67% confidence The document is a regulatory notice titled “주권매매거래정지” (Trading Suspension) issued under KOSDAQ rules, stating that shares will be suspended from trading due to a corporate action—specifically a share consolidation (“주식병합”) and subsequent new-share listing. This fits under the “Share Issue/Capital Change” category (Code: SHA), which covers announcements on stock splits, consolidations, and other capital changes.
2026-05-12 Korean
투자판단관련주요경영사항(임상시험계획자진취하등) (NTI7(NIT119, 비소세포폐암) 임상 2상 시험 자진취하)
Regulatory Filings Classification · 88% confidence The document is a Korean ‘투자판단 관련 주요경영사항’ disclosure regarding voluntary withdrawal of a clinical trial plan. It is a regulatory announcement of a material event that does not fit any other more specific category (e.g., earnings, board changes, dividends) and thus falls under general regulatory filings.
2026-04-24 Korean
[기재정정]주식병합결정
Share Issue/Capital Change Classification · 90% confidence The document is a corporate announcement detailing the decision to consolidate (reverse split) shares, including the ratio, effective dates, trading suspension period, and related schedule. It is not a full financial report, earnings release, or AGM material but a capital change announcement. This aligns with the “Share Issue/Capital Change” category.
2026-04-23 Korean
[기재정정]증권예탁증권(DR)병합결정
Share Issue/Capital Change Classification · 85% confidence The text is a Korean stock exchange disclosure announcing and correcting the schedule for a depositary receipt (DR) consolidation (reverse stock split) – a corporate action altering the share capital structure. This falls under the category of share issues and capital changes. It is not a formal annual report or earnings release but a notice of share consolidation. Therefore, it should be classified as a Share Issue/Capital Change (SHA).
2026-04-23 Korean

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.